Novo Nordisk Reports P-IIIa (ONWARDS 3 & 4) Trials Results of Insulin Icodec for the Treatment of Type 2 Diabetes
- The P-IIIa (ONWARDS 3 & 4) trials evaluating efficacy & safety treat-to-target trial of insulin icodec (qw) vs insulin degludec & insulin glargine U100 in combination with mealtime insulin in 588 & 582 patients with T2D. The results from (ONWARDS 5) trial are expected in H2'22
- The P-IIIa (ONWARDS 3 & 4) trials meet its 1EPs & showed non-inferiority in reducing HbA1c @26wk. with insulin icodec over insulin degludec & insulin glargine
- Superior reduction in estimated HbA1c of –1.57% & –1.16% vs –1.36% & –1.18% from an overall baseline HbA1c of 8.5% & 8.3%, no significant difference in estimated rates of sev. or clinically significant hypoglycaemia with 0.31 & 5.64 vs 0.15 & 5.62 event per patient yr., was safe & well-tolerated
Ref: Globenewswire | Image: Novo Nordisk
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.